ArticleMolecular cancer2010
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.Cancer management and research · 2025Review
- Novel mouse model of indwelling pleural catheter in mice with malignant pleural effusion.ERJ open research · 2019Article
- Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.Nature communications · 2018Article
- Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.Oncotarget · 2017Article
- Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Malignant pleural effusion: from bench to bedside.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.Journal of translational medicine · 2015Article
- Switching off malignant pleural effusion formation-fantasy or future?Journal of thoracic disease · 2015Review
- Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study.Pharmacology research & perspectives · 2014Article
- Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.Oncogene · 2013Article
- Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.PloS one · 2013Article
- Malignant pleural effusion: tumor-host interactions unleashed.American journal of respiratory and critical care medicine · 2012Review
- Malignant pleural effusion: further translational research is crucial.Translational lung cancer research · 2012Article
- Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.Translational lung cancer research · 2012Article
- Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.Carcinogenesis · 2012Article
- NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target.Frontiers in bioscience (Landmark edition) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have previously shown that nuclear factor (NF)-kappaB activation of mouse Lewis lung carcinoma (LLC) specifically promotes the induction of malignant pleural effusions (MPE) by these cells. In the present studies we hypothesized that treatment of immunocompetent mice with bortezomib tailored to inhibit cancer cell NF-kappaB activation and not proliferation specifically inhibits MPE formation by LLC cells.
resultsTreatment of LLC cells with low concentrations of bortezomib (100 ng/ml) inhibited NF-kappaB activation and NF-kappaB-dependent transcription, but not cellular proliferation. Bortezomib treatment of immunocompetent C57BL/6 mice bearing LLC-induced subcutaneous tumors and MPEs significantly blocked tumor-specific NF-kappaB activation. However, bortezomib treatment did not impair subcutaneous LLC tumor growth, but was effective in limiting LLC-induced MPE. This specific effect was evidenced by significant reductions in effusion accumulation and the associated mortality and was observed with both preventive (beginning before MPE formation) and therapeutic (beginning after MPE establishment) bortezomib treatment. The favorable impact of bortezomib on MPE was associated with suppression of cardinal MPE-associated phenomena, such as inflammation, vascular hyperpermeability, and angiogenesis. In this regard, therapeutic bortezomib treatment had identical favorable results on MPE compared with preventive treatment, indicating that the drug specifically counteracts effusion formation.
conclusionsThese studies indicate that proteasome inhibition tailored to block NF-kappaB activation of lung adenocarcinoma specifically targets the effusion-inducing phenotype of this tumor. Although the drug has limited activity against advanced solid lung cancer, it may prove beneficial for patients with MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.